Product Information

GABAPENTIN 400 MG CAPSULE is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $0.0435 per EA under NDC 76282032305. Its NADAC has been published 390 times since Jun 5, 2019.

FDA first approved this application on Dec 30, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

GABAPENTIN 400 MG CAPSULE

GABAPENTIN
$0.0435per EA

Strength

400 mg/1

NDC

76282032305

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

GABAPENTIN

Approval Type

Generic (ANDA)

FDA Application

ANDA090705

FDA Approved

12/30/2009

TE Code

AB

On Market Since

4/26/2010

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for GABAPENTIN 400 MG CAPSULE has been published 390 times since Jun 5, 2019, and over the history we have for it it has declined 36.0%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0435 per EA
All-time high$0.0743 (Jun 16, 2021)
All-time low$0.0396 (Apr 22, 2026)
52-week high$0.0435
52-week low$0.0396
Median price$0.0571
Average price$0.0562
Largest weekly change+23.4% (Aug 21, 2024)
Weeks tracked390
Tracking sinceJun 5, 2019

Price History

1W

+1.5%

1M

+3.0%

3M

+8.8%

6M

+6.9%

1Y

+4.6%

3Y

-20.1%

5Y

-29.1%

All

-36.0%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of GABAPENTIN 400 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 400 MG CAPSULE, manufactured by Exelan Pharmaceuticals Inc., is $0.0435 per EA (NDC 76282032305), effective Nov 18, 2026.

How has the price of GABAPENTIN 400 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for GABAPENTIN 400 MG CAPSULE has declined 36.0%. It has been tracked across 390 weekly CMS publications since Jun 5, 2019.

What are the highest and lowest recorded NADAC prices for GABAPENTIN 400 MG CAPSULE?

Since Jun 5, 2019, the NADAC for GABAPENTIN 400 MG CAPSULE has ranged from a low of $0.0396 (Apr 22, 2026) to a high of $0.0743 (Jun 16, 2021), with a median of $0.0571 per EA.

Are there cheaper alternatives to GABAPENTIN 400 MG CAPSULE?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 400 MG CAPSULE, is $0.0416 per EA — about 4% below GABAPENTIN 400 MG CAPSULE.

Who manufactures GABAPENTIN 400 MG CAPSULE?

GABAPENTIN 400 MG CAPSULE (NDC 76282032305) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.